NASDAQ:ACER

Acer Therapeutics - ACER Stock Forecast, Price & News

$0.75

-0.01 (-1.32%)

(As of 03/30/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.73
▼
$0.79
50-Day Range: $0.67
▼
$2.42
52-Week Range: $0.65
▼
$4.56

Volume: 321,439 shs
Average Volume: 452,537 shs
Market Capitalization: $15.80 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

Acer Therapeutics MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.61% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.71
Based on 9 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.23) to $0.71 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.51 out of 5 stars

Medical Sector

902nd out of 1,009 stocks

Pharmaceutical Preparations Industry

439th out of 494 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Acer Therapeutics.

3.0

Short Interest

Percentage of Shares Shorted
1.61% of the outstanding shares of Acer Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Acer Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Acer Therapeutics has recently increased by 14.41%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Acer Therapeutics does not currently pay a dividend.
Dividend Growth
Acer Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACER.

3.2

News and Social Media Coverage

News Sentiment
Acer Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Acer Therapeutics this week, compared to 2 articles on an average week.
Search Interest
13 people have searched for ACER on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.
MarketBeat Follows
4 people have added Acer Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Acer Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
20.20% of the stock of Acer Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 27.96% of the stock of Acer Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Acer Therapeutics are expected to grow in the coming year, from ($0.23) to $0.71 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Acer Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Acer Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Acer Therapeutics (NASDAQ:ACER) Stock

Acer Therapeutics, Inc. is a pharmaceutical company. engages in acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes ACER-001 Edsivo and ACER-2820. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded on March 15, 1991 and is headquartered in Newton, MA.

Receive ACER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acer Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACER Stock News Headlines

March 30, 2023 | americanbankingnews.com

Equities Analysts Set Expectations for Acer Therapeutics Inc.'s Q1 2023 Earnings (NASDAQ:ACER)

March 29, 2023 | finanznachrichten.de

Acer Therapeutics Inc.: Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update

March 30, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

March 27, 2023 | finance.yahoo.com

Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update

March 22, 2023 | finanznachrichten.de

Acer Therapeutics Inc.: Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

March 22, 2023 | tmcnet.com

Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder

March 22, 2023 | finance.yahoo.com

Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

March 22, 2023 | finance.yahoo.com

Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes

March 30, 2023 | Weiss Ratings (Ad)

Bank Accounts: Frozen!

In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!

March 17, 2023 | reuters.com

Two new vaccines against bird flu effective in Dutch lab -govt

March 17, 2023 | reuters.com

UK healthcare workers to decide on new pay offer by end of April -unions

March 17, 2023 | finanznachrichten.de

Acer Therapeutics Inc.: Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial

March 17, 2023 | seekingalpha.com

Acer stock slumps ~45% as ACER-801 paused after hot flashes trial disappoints; cash woes

March 17, 2023 | marketwatch.com

Acer Therapeutics Shares Hit 52-Week Low After ACER-801 Trial Misses Topline Results

March 17, 2023 | reuters.com

Acer Therapeutics to pause trial of hot flashes drug

March 17, 2023 | bizjournals.com

Newton biotech's drug for hot flashes due to menopause fails trial

March 17, 2023 | finance.yahoo.com

Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study

March 17, 2023 | finance.yahoo.com

Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial

March 15, 2023 | finance.yahoo.com

Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides OLPRUVA™ Program Update

March 15, 2023 | uk.finance.yahoo.com

Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA™

March 15, 2023 | finance.yahoo.com

Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA

February 18, 2023 | finance.yahoo.com

ACER Feb 2023 2.500 call

February 14, 2023 | finance.yahoo.com

Acer Therapeutics Inc. (ACER) Interactive Stock Chart - Yahoo Finance

February 13, 2023 | finance.yahoo.com

Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

February 10, 2023 | finance.yahoo.com

Acer (ACER) to Report Q4 Earnings: What's in the Cards?

January 27, 2023 | forbes.com

Acer Therapeutics

January 25, 2023 | finance.yahoo.com

Acer Therapeutics Inc. (ACER) Gains As Market Dips: What You Should Know

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ACER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acer Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACER Company Calendar

Last Earnings: 11/19/2021
Today: 3/30/2023
Next Earnings (Estimated): 5/15/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ACER
CUSIP: N/A
CIK: 1069308
Web: www.acertx.com
Phone: (844) 902-6100
Fax: 281-872-8585
Employees: 35
Year Founded: 2013

Profitability

EPS (Most Recent Fiscal Year): ($1.66)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-15,370,000.00
Net Margins: N/A
Pretax Margin: -5,909.44%
Return on Equity: N/A
Return on Assets: -107.05%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.35
Quick Ratio: 0.35

Sales & Book Value

Annual Sales: $1.26 million
Price / Sales: 12.54
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.12) per share
Price / Book: -6.25

Miscellaneous

Outstanding Shares: 21,070,000
Free Float: 16,813,000
Market Cap: $15.80 million
Optionable: Not Optionable
Beta: 0.65

Social Links

Key Executives

Christopher Schelling
President, Chief Executive Officer & Director

Tanya Hayden
Chief Operating Officer

Harry S. Palmin
Chief Financial Officer

Stacey Bain
Vice President-Clinical Operations

Adrian Quartel
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACER Stock - Frequently Asked Questions

How have ACER shares performed in 2023?: Acer Therapeutics' stock was trading at $2.51 at the beginning of 2023. Since then, ACER shares have decreased by 70.1% and is now trading at $0.75.
View the best growth stocks for 2023 here.
Are investors shorting Acer Therapeutics?: Acer Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 338,200 shares, an increase of 14.4% from the February 28th total of 295,600 shares. Based on an average daily volume of 556,500 shares, the days-to-cover ratio is currently 0.6 days.
View Acer Therapeutics' Short Interest.
When is Acer Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our ACER earnings forecast.
How were Acer Therapeutics' earnings last quarter?: Acer Therapeutics Inc. (NASDAQ:ACER) released its earnings results on Friday, November, 19th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.05.
What is Jason Chen's approval rating as Acer Therapeutics' CEO?: 64 employees have rated Acer Therapeutics Chief Executive Officer Jason Chen on Glassdoor.com. Jason Chen has an approval rating of 99% among the company's employees. This puts Jason Chen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Acer Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), Amarin (AMRN), VBI Vaccines (VBIV), NVIDIA (NVDA), Idera Pharmaceuticals (IDRA) and Inovio Pharmaceuticals (INO).

What is Acer Therapeutics' stock symbol?: Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."
Who are Acer Therapeutics' major shareholders?: Acer Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Nantahala Capital Management LLC (7.69%), Knott David M Jr (0.88%), Geode Capital Management LLC (0.60%), Meridian Wealth Management LLC (0.45%), Renaissance Technologies LLC (0.37%) and SVB Wealth LLC (0.07%). Insiders that own company stock include Chris Schelling, Donald Joseph and Steve Aselage.
View institutional ownership trends.
How do I buy shares of Acer Therapeutics?: Shares of ACER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Acer Therapeutics' stock price today?: One share of ACER stock can currently be purchased for approximately $0.75.
How much money does Acer Therapeutics make?: Acer Therapeutics (NASDAQ:ACER) has a market capitalization of $15.80 million and generates $1.26 million in revenue each year. The biopharmaceutical company earns $-15,370,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.
Does Acer Therapeutics have any subsidiaries?: The following companies are subsidiares of Acer Therapeutics: Opexa Therapeutics Inc..
Read More
How can I contact Acer Therapeutics?: Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The official website for the company is www.acertx.com. The biopharmaceutical company can be reached via phone at (844) 902-6100, via email at hans@lifesciadvisors.com, or via fax at 281-872-8585.

This page (NASDAQ:ACER) was last updated on 3/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Acer Therapeutics - ACER Stock Forecast, Price & News

Acer Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Acer Therapeutics (NASDAQ:ACER) Stock

ACER Stock News Headlines

ACER Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

ACER Stock - Frequently Asked Questions

Overall MarketRank^™